Latest news with #GiantBiogene
South China Morning Post
18-05-2025
- Business
- South China Morning Post
Who is Fan Daidi? New vice-president of top China university has net worth of US$6 billion
The newly-appointed vice-president of a top university in China has trended on social media after she was revealed to be the richest person in the country's northwestern Shaanxi province. Fan Daidi possibly also has the highest net worth of all university executives in the country. In April, Fan, 59, was named the vice-president of Northwest University in Xi'an, Shaanxi province, she was placed in charge of international cooperation. But she has attracted more attention because of her other roles. Fan and her husband Yan Jianya are founders of the Hong Kong-listed biological medicine enterprise Giant Biogene. They also hold a significant share in the Shenzhen-listed aviation material company Triangle Defense.
South China Morning Post
17-05-2025
- Business
- South China Morning Post
The Chinese chemists turning science into fortunes
Fan Daidi, a 59-year-old chemistry professor turned billionaire entrepreneur, epitomises China's booming chemical sciences sector. Advertisement As dean of Northwest University's chemical engineering school in Xian, Fan has amassed a fortune by commercialising innovations in collagen synthesis , catapulting her skincare enterprise Giant Biogene to a 75 billion yuan (US$10.4 billion) valuation. Fan's ascent – from pioneering lab discoveries to leading a biomedical empire – highlights how state-backed scientific industrialisation is minting a new generation of academic tycoons. According to a report by Shenzhen-based New Fortune magazine on May 9, Fan and her husband Yan Jianya's combined holdings are estimated to be valued at more than 40 billion yuan. Advertisement The couple own two major companies – Giant Biogene and XiAn Triangle Defence – which operate in the pharmaceutical and aerospace industries, respectively.
Reuters
16-04-2025
- Business
- Reuters
China's Giant Biogene raises about $301 million in Hong Kong share sale, term sheet shows
SYDNEY, April 17 (Reuters) - China's Giant Biogene has raised about $301 million in a Hong Kong top up placement, according to a term sheet seen by Reuters. The company sold 35 million shares at HK$66.65, a 9.5% discount to Giant Biogene's closing price on the Hong Kong Stock Exchange on Wednesday, the term sheet showed. The final price was at the bottom end of the price range flagged to investors when the deal launched. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
